Owen Martyn Bendor-Samuel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Owen Martyn Bendor-Samuel has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Alice Adriaenssens
Department of Neuroscience, Physiology, and Pharmacology University College London London UK
2 shared publications - Amelia K. Linnemann
Department of Pediatrics Indiana University School of Medicine Indianapolis Indiana USA
2 shared publications Andreas Oder
Leibniz‐Forschungsinstitut für Molekulare Pharmakologie Berlin Germany
2 shared publications- Ben Jones
Section of Endocrinology Imperial College London London UK
2 shared publications - Christopher Carlein
Radcliffe Department of Medicine Oxford Centre for Diabetes Endocrinology and Metabolism (OCDEM) NIHR Oxford Biomedical Research Centre Bukhman Centre for Research Excellence in Type 1 Diabetes Churchill Hospital University of Oxford Oxford UK
2 shared publications - David J. Hodson
Radcliffe Department of Medicine Oxford Centre for Diabetes Endocrinology and Metabolism (OCDEM) NIHR Oxford Biomedical Research Centre Bukhman Centre for Research Excellence in Type 1 Diabetes Churchill Hospital University of Oxford Oxford UK
2 shared publications
Latest Publications
- Open Access
- 30 October 2026
- Published by Wiley in Angewandte Chemie
- p. e4679620
A Precision‐Delivered Singlet Oxygen Generator With an Inbuilt Safety Switch for Induction of Pancreatic Beta Cell Stress and Death
Type 1 diabetes (T1D) is characterized by autoimmune destruction of pancreatic beta cells, leading to insulin dependence. Preclinical models have been instrumental in advancing our understanding of the pathogenesis and treatment of T1D. Chemical agents such as streptozotocin or alloxan are widely used to induce beta cell destruction without the need for genetic alteration. However, streptozotocin and alloxan exhibit variable efficacy, can be taken up non‐specifically into other organs, and possess carcinogenic properties. As such, there is a need for more specific and less toxic models of beta cell stress. Here, we design and evaluate ROXendin668, a glucagon‐like peptide‐1 receptor (GLP1R) agonist coupled to a singlet oxygen ( 1 O 2 ) sensitizer. ROXendin668 targets pancreatic beta cells through engagement of GLP1R and potentially GCGR, followed by red light‐controlled generation of 1 O 2 . Upon illumination, ROXendin668 selectively ablates MIN6 β‐cells and primary islet β‐cells and induces localized β‐cell stress in vivo after systemic delivery. Thus, ROXendin668 represents a precise, controllable, and potentially safer alternative to existing chemical models of beta cell stress.
- 30 October 2026
- Published by Wiley in Angewandte Chemie
- p. e4679620
Open AccessA Precision‐Delivered Singlet Oxygen Generator With an Inbuilt Safety Switch for Induction of Pancreatic Beta Cell Stress and Death
Type 1 diabetes (T1D) is characterized by autoimmune destruction of pancreatic beta cells, leading to insulin dependence. Preclinical models have been instrumental in advancing our understanding of the pathogenesis and treatment of T1D. Chemical agents such as streptozotocin or alloxan are widely used to induce beta cell destruction without the need for genetic alteration. However, streptozotocin and alloxan exhibit variable efficacy, can be taken up non‐specifically into other organs, and possess carcinogenic properties. As such, there is a need for more specific and less toxic models of beta cell stress. Here, we design and evaluate ROXendin668, a glucagon‐like peptide‐1 receptor (GLP1R) agonist coupled to a singlet oxygen ( 1 O 2 ) sensitizer. ROXendin668 targets pancreatic beta cells through engagement of GLP1R and potentially GCGR, followed by red light‐controlled generation of 1 O 2 . Upon illumination, ROXendin668 selectively ablates MIN6 β‐cells and primary islet β‐cells and induces localized β‐cell stress in vivo after systemic delivery. Thus, ROXendin668 represents a precise, controllable, and potentially safer alternative to existing chemical models of beta cell stress.
- Open Access
- 30 October 2026
- Published by Wiley in Angewandte Chemie International Edition
- p. e4679620
A Precision‐Delivered Singlet Oxygen Generator With an Inbuilt Safety Switch for Induction of Pancreatic Beta Cell Stress and Death
Type 1 diabetes (T1D) is characterized by autoimmune destruction of pancreatic beta cells, leading to insulin dependence. Preclinical models have been instrumental in advancing our understanding of the pathogenesis and treatment of T1D. Chemical agents such as streptozotocin or alloxan are widely used to induce beta cell destruction without the need for genetic alteration. However, streptozotocin and alloxan exhibit variable efficacy, can be taken up non‐specifically into other organs, and possess carcinogenic properties. As such, there is a need for more specific and less toxic models of beta cell stress. Here, we design and evaluate ROXendin668, a glucagon‐like peptide‐1 receptor (GLP1R) agonist coupled to a singlet oxygen ( 1 O 2 ) sensitizer. ROXendin668 targets pancreatic beta cells through engagement of GLP1R and potentially GCGR, followed by red light‐controlled generation of 1 O 2 . Upon illumination, ROXendin668 selectively ablates MIN6 β‐cells and primary islet β‐cells and induces localized β‐cell stress in vivo after systemic delivery. Thus, ROXendin668 represents a precise, controllable, and potentially safer alternative to existing chemical models of beta cell stress.
- 30 October 2026
- Published by Wiley in Angewandte Chemie International Edition
- p. e4679620
Open AccessA Precision‐Delivered Singlet Oxygen Generator With an Inbuilt Safety Switch for Induction of Pancreatic Beta Cell Stress and Death
Type 1 diabetes (T1D) is characterized by autoimmune destruction of pancreatic beta cells, leading to insulin dependence. Preclinical models have been instrumental in advancing our understanding of the pathogenesis and treatment of T1D. Chemical agents such as streptozotocin or alloxan are widely used to induce beta cell destruction without the need for genetic alteration. However, streptozotocin and alloxan exhibit variable efficacy, can be taken up non‐specifically into other organs, and possess carcinogenic properties. As such, there is a need for more specific and less toxic models of beta cell stress. Here, we design and evaluate ROXendin668, a glucagon‐like peptide‐1 receptor (GLP1R) agonist coupled to a singlet oxygen ( 1 O 2 ) sensitizer. ROXendin668 targets pancreatic beta cells through engagement of GLP1R and potentially GCGR, followed by red light‐controlled generation of 1 O 2 . Upon illumination, ROXendin668 selectively ablates MIN6 β‐cells and primary islet β‐cells and induces localized β‐cell stress in vivo after systemic delivery. Thus, ROXendin668 represents a precise, controllable, and potentially safer alternative to existing chemical models of beta cell stress.
- Open Access
- 28 September 2022
- Published by BMJ in Archives of Disease in Childhood
- Vol. 108 (1) , 26-30
Successful integration of newborn genetic testing into UK routine screening using prospective consent to determine eligibility for clinical trials
Objective INGR1D (INvestigating Genetic Risk for type 1 Diabetes) was a type 1 diabetes (T1D) genetic screening study established to identify participants for a primary prevention trial (POInT, Primary Oral Insulin Trial). Methods The majority of participants were recruited by research midwives in antenatal clinics from 18 weeks’ gestation. Using the NHS Newborn Bloodspot Screening Programme (NBSP) infrastructure, participants enrolled in INGR1D had an extra sample taken from their day 5 bloodspot card sent for T1D genetic screening. Those at an increased risk of T1D were informed of the result, given education about T1D and the opportunity to take part in POInT. Results Between April 2018 and November 2020, 66% of women approached about INGR1D chose to participate. 15 660 babies were enrolled into INGR1D and 14 731 blood samples were processed. Of the processed samples, 157 (1%) had confirmed positive results, indicating an increased risk of T1D, of whom a third (n=49) enrolled into POInT (20 families were unable to participate in POInT due to COVID-19 lockdown restrictions). Conclusion The use of prospective consent to perform personalised genetic testing on samples obtained through the routine NBSP represents a novel mechanism for clinical genetic research in the UK and provides a model for further population-based genetic studies in the newborn.
- 28 September 2022
- Published by BMJ in Archives of Disease in Childhood
- Vol. 108 (1) , 26-30
Open AccessSuccessful integration of newborn genetic testing into UK routine screening using prospective consent to determine eligibility for clinical trials
Objective INGR1D (INvestigating Genetic Risk for type 1 Diabetes) was a type 1 diabetes (T1D) genetic screening study established to identify participants for a primary prevention trial (POInT, Primary Oral Insulin Trial). Methods The majority of participants were recruited by research midwives in antenatal clinics from 18 weeks’ gestation. Using the NHS Newborn Bloodspot Screening Programme (NBSP) infrastructure, participants enrolled in INGR1D had an extra sample taken from their day 5 bloodspot card sent for T1D genetic screening. Those at an increased risk of T1D were informed of the result, given education about T1D and the opportunity to take part in POInT. Results Between April 2018 and November 2020, 66% of women approached about INGR1D chose to participate. 15 660 babies were enrolled into INGR1D and 14 731 blood samples were processed. Of the processed samples, 157 (1%) had confirmed positive results, indicating an increased risk of T1D, of whom a third (n=49) enrolled into POInT (20 families were unable to participate in POInT due to COVID-19 lockdown restrictions). Conclusion The use of prospective consent to perform personalised genetic testing on samples obtained through the routine NBSP represents a novel mechanism for clinical genetic research in the UK and provides a model for further population-based genetic studies in the newborn.
- 12 May 2020
- Published by S. Karger AG in Neonatology
- Vol. 117 (3) , 300-307
A Comparison of UK Preterm Anthropometric Charts and INTERGROWTH-21st: Is It Time to Change Growth Charts?
Background: Current practice in the UK is to plot premature infant anthropometric measurements on Neonatal and Infant Close Monitoring (NICM) reference charts. These charts have several known limitations. The INTERGROWTH-21st Project has recently produced international ante- and postnatal growth standards. Exact knowledge of growth centiles allows clinicians to accurately assess infant nutritional requirements. Objective: To compare target centile measurements between INTERGROWTH-21st and UK NICM growth charts for premature infants. Method: Anthropometric measurements (weight and head circumference) of a convenience sample of neonates born between 24 and 32 weeks of gestation were analysed retrospectively. Measurements were collected across three time points and plotted on both the NICM and INTERGROWTH-21st growth charts. The respective centiles were compared and analysed by paired-sample t test, Wilcoxon rank test analysis, and multilevel mixed-effect linear regression models. Results: Centiles for weight and head circumference measurements of 96 infants plotted on INTERGROWTH-21st charts were significantly greater than their corresponding UK charts at all three time points. For weight, the average difference between the two charts varied from 9.1 to 16.4 centiles. The difference between the two charts was greater for female than male infants by up to 6.9 centiles (95% CI 10.1–3.8). Conclusion: Existing UK NICM reference charts are significantly different to the growth standards of INTERGROWTH-21st. The choice of which growth chart to adopt in the UK could have important consequences on premature infants’ future adult health and therefore requires further prospective observational studies with larger data sets including length measurements and more comprehensive population characteristics.
- 12 May 2020
- Published by S. Karger AG in Neonatology
- Vol. 117 (3) , 300-307
A Comparison of UK Preterm Anthropometric Charts and INTERGROWTH-21st: Is It Time to Change Growth Charts?
Background: Current practice in the UK is to plot premature infant anthropometric measurements on Neonatal and Infant Close Monitoring (NICM) reference charts. These charts have several known limitations. The INTERGROWTH-21st Project has recently produced international ante- and postnatal growth standards. Exact knowledge of growth centiles allows clinicians to accurately assess infant nutritional requirements. Objective: To compare target centile measurements between INTERGROWTH-21st and UK NICM growth charts for premature infants. Method: Anthropometric measurements (weight and head circumference) of a convenience sample of neonates born between 24 and 32 weeks of gestation were analysed retrospectively. Measurements were collected across three time points and plotted on both the NICM and INTERGROWTH-21st growth charts. The respective centiles were compared and analysed by paired-sample t test, Wilcoxon rank test analysis, and multilevel mixed-effect linear regression models. Results: Centiles for weight and head circumference measurements of 96 infants plotted on INTERGROWTH-21st charts were significantly greater than their corresponding UK charts at all three time points. For weight, the average difference between the two charts varied from 9.1 to 16.4 centiles. The difference between the two charts was greater for female than male infants by up to 6.9 centiles (95% CI 10.1–3.8). Conclusion: Existing UK NICM reference charts are significantly different to the growth standards of INTERGROWTH-21st. The choice of which growth chart to adopt in the UK could have important consequences on premature infants’ future adult health and therefore requires further prospective observational studies with larger data sets including length measurements and more comprehensive population characteristics.
- 4 April 2019
- Published by BMJ in Archives of Disease in Childhood - Education & Practice Edition
- Vol. 105 (2) , 111-116
Pituitary gigantism: a rare learning opportunity
Introduction Pituitary gigantism is a rare but significant paediatric condition with complexities surrounding diagnosis and management. Transsphenoidal surgery (TSS) is the treatment of choice; however, medical treatment is often considered as adjuvant therapy. Case A 10½ -year-old boy presented with tall stature and a height velocity of 11 cm/year. His height was 178.7 cm (+5.8 SD above mean) and insulin-like growth factor-1 (IGF-1) was elevated. An oral glucose tolerance test demonstrated non-suppression of growth hormone (GH). Initial contrast MRI was inconclusive, but C-11 methionine functional positron emission tomography CT identified a 6 mm pituitary microadenoma. A multidisciplinary team clinic held with the family allowed discussion about medical and surgical treatment options. Due to a number of factors including the patient’s young age, prepubertal status, a wish to allow him to settle into his new high school and his desire to reach a final height taller than his father’s height, it was decided to try medical therapy first with a somatostatin analogue. Pubertal induction was also commenced and bilateral epiphysiodesis surgery performed. Initial response to octreotide was positive; however, 4 months into therapy his IGF-1 was climbing and a repeat GH profile was not fully suppressed. The patient therefore proceeded to have successful TSS excision of the adenoma. Conclusion Rare cases such as this require sharing of knowledge and expertise, so the best possible care is offered. It is often necessary to work across sites and disciplines. Each case requires an individual approach tailored to the patient and their family.
- 4 April 2019
- Published by BMJ in Archives of Disease in Childhood - Education & Practice Edition
- Vol. 105 (2) , 111-116
Pituitary gigantism: a rare learning opportunity
Introduction Pituitary gigantism is a rare but significant paediatric condition with complexities surrounding diagnosis and management. Transsphenoidal surgery (TSS) is the treatment of choice; however, medical treatment is often considered as adjuvant therapy. Case A 10½ -year-old boy presented with tall stature and a height velocity of 11 cm/year. His height was 178.7 cm (+5.8 SD above mean) and insulin-like growth factor-1 (IGF-1) was elevated. An oral glucose tolerance test demonstrated non-suppression of growth hormone (GH). Initial contrast MRI was inconclusive, but C-11 methionine functional positron emission tomography CT identified a 6 mm pituitary microadenoma. A multidisciplinary team clinic held with the family allowed discussion about medical and surgical treatment options. Due to a number of factors including the patient’s young age, prepubertal status, a wish to allow him to settle into his new high school and his desire to reach a final height taller than his father’s height, it was decided to try medical therapy first with a somatostatin analogue. Pubertal induction was also commenced and bilateral epiphysiodesis surgery performed. Initial response to octreotide was positive; however, 4 months into therapy his IGF-1 was climbing and a repeat GH profile was not fully suppressed. The patient therefore proceeded to have successful TSS excision of the adenoma. Conclusion Rare cases such as this require sharing of knowledge and expertise, so the best possible care is offered. It is often necessary to work across sites and disciplines. Each case requires an individual approach tailored to the patient and their family.